Enchanted World Inc. (ENCW)

[Physics-N-Trading]

OTCPicks.com: OTCPicks.com Daily Market Movers Digest Midday Report for Wednesday, April 9th MPPC, EPMD, FVRL, CIRT, CWRM

Apr 09, 2008 (M2 PRESSWIRE via COMTEX) -- Our Stocks to Watch today include myPhotopipe.com Inc. (OTC: MPPC), EP MedSystems Inc. (NASD: EPMD), Favrille Inc. (NASD: FVRL), Cardio Infrared Technologies Inc. (OTC: CIRT), Cotton & Western Mining Inc. (OTC: CWRM)
Visit http://www.otcpicks.com to register for our Daily Market Mover's Digest Newsletter, and Email Stock Watch Alerts.

MYPHOTOPIPE.COM INCORPORATED (OTC: MPPC)

Detailed Quote: http://www.otcpicks.com/quotes/MPPC.php

Company Profile: http://www.otcpicks.com/myphotopipe/myphotopipe-2.htm

MyPhotopipe.com Inc. is a US-based provider of online digital photo processing and related services catering to high-end amateur and professional photographers. The Company's primary web portal is www.myphotopipe.com. Its services include photo finishing and printing, online sharing, photo books, digital photo templates, and online hosting and selling of photographs. The Company provides services to more than 18,500 professional and high-end amateur photographers nationwide; more than 190,000 copies of its software have been downloaded and are in use.

MPPC News:

April 9 - myPhotopipe.com Expands Online Offering of Photo Greeting Cards

Company targets $7.5 billion greeting card space with more than 300 new products

myPhotopipe.com, Inc. (OTC: MPPC), a web-based online provider of digital photo processing and related services, unveiled a new initiative to significantly expand its product offerings and presence in the photo greeting card segment of the $7.5 billion greeting card market. The Company expects to more than double the number of products offered via its online web portal, www.myphotopipe.com.

During 2006, according to data from industry association PMA, over 9 million households used digital cameras to make photo greeting cards, spending more than $550 million. As in years past, owners of high-end digital cameras (8 megapixels or more) were almost twice as likely to make photo greeting cards as owners of lower resolution cameras. What prompted myPhotopipe.com's newly announced initiative was the sharp increase in sales of high-end cameras.

According to PMA data, demand for 8 or greater megapixel cameras grew at a rate of 977% in the fourth quarter of 2007, versus the same period in 2006. This translates into approximately 25 million new high-end cameras entering the US market in 2007. According to the PMA, better cameras correlate to better images. This, in turn, encourages the purchase of more photo cards, which have also benefited from an increasing demand among consumers for self-expression and the personalization of social sentiments.

myPhotopipe.com offered consumers 629 photo greeting card styles at the end of 2007. The Company is adding 256 cards under its newly created Designer Collection category and 60 cards under a new General Purpose category, and it will also expand all of its existing categories with a new line of primary colors.

"This is the single most important initiative we have undertaken since the launch of FolioPrints," noted Eric Casolo, Director of Digital Photo Tools for the Company. "In large measure it came about because of the convergence in data and trends. First there was the jump in sales of high-resolution cameras. Second, the whole social expressions segment of the greeting card market has doubled during the past two years. And of course, owners of high-end cameras are almost twice as likely to make photo cards as the ordinary digital camera owner. When we saw the sharp increase in demand for cameras with resolutions of 8 megapixels and higher, we felt compelled to act, so we accelerated our timetables and will continue on an accelerated pace for the next two months."

According to the PMA, photo greeting cards grew from 270 million units in 2005 to 550 million in 2006. Year-end data for 2007 is not yet available.

EP MEDSYSTEMS INCORPORATED (NASD: EPMD) "Up 102.84% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/EPMD.php

EP MedSystems, Inc. engages in the development, manufacture, and marketing of a line of products for the cardiac electrophysiology market to diagnose, monitor, visualize, and treat arrhythmias. The company's products include EP-WorkMate system, a computerized electrophysiology workstation that monitors, displays, and stores cardiac electrical activity and arrhythmia data; EP-4 Computerized Cardiac Stimulator, which is used to stimulate the heart with electrical impulses to locate electrical disturbances; and MapMate interface that enables EP-WorkMate system to share information, log data, and generate a common report with the CARTO Mapping navigation system. It also offers intracardiac ultrasound imaging, including ViewMate ultrasound imaging console and ViewFlex intracardiac imaging catheters for the treatment of atrial fibrillation and ventricular tachycardias. In addition, the company provides the ALERT System that uses an electrode catheter to deliver bi-phasic electrical impulses directly to the inside of the heart to convert atrial fibrillation to a normal heart rhythm; and diagnostic electrophysiology catheters for stimulation and sensing of electrical signals during electrophysiology studies. EP MedSystems sells its products directly to medical institutions and physicians in the United States and France, as well as to a network of distributors in Europe, the Middle East, and Asia. It has strategic alliances with Philips Medical Systems Nederland B.V. and Biosense Webster, Inc. The company was founded in 1993 and is based in West Berlin, New Jersey.

EPMD News:

April 9 - St. Jude Medical to Acquire EP MedSystems

St. Jude Medical, Inc. (NYSE: STJ) and EP MedSystems, Inc. (NASD: EPMD) announced that the Boards of Directors of both companies have unanimously approved a definitive merger agreement under which St. Jude Medical will acquire EP MedSystems for approximately $92.1 million.

Terms of the Agreement:

Under the terms of the merger agreement, EP MedSystems shareholders will receive $3.00 of consideration for each EP MedSystems share they own, with the option of receiving that amount in cash or St. Jude Medical common stock. The number of shares of St. Jude Medical common stock that EP MedSystems shareholders will receive will be determined based on the average closing price over 10 trading days, ending on the second business day before the transaction closes. The cash and stock elections are subject to pro-ration such that St. Jude Medical will issue 40 percent of the total merger consideration in St. Jude Medical common stock and 60 percent in cash.

In connection with this transaction, St. Jude Medical's Board of Directors has approved an additional stock buyback authorization of $50 million, which increases St. Jude Medical's share repurchase authorization from $250 million to $300 million. The additional buyback authorization will be used to offset the shares issued in this transaction.

The companies anticipate this acquisition will close during the third quarter of 2008. In connection with this transaction, St. Jude Medical will record a special charge for in-process R&D. This acquisition does not change St. Jude Medical's existing guidance for 2008 earnings per share, exclusive of the special charge.

Acceleration of St. Jude Medical's AF Program:

Upon completion, this transaction will immediately add two new growth drivers to St. Jude Medical's program for products used in atrial fibrillation (AF) and other electrophysiology (EP) catheterization procedures. This includes the EP-WorkMate computerized electrophysiology workstation with a fully integrated EP-4 Computerized Cardiac Stimulator and expansion options to incorporate the NurseMate Remote Review Charting Station. The EP-WorkMate platform already enjoys a strong number two share of the global market for EP recording systems in spite of limited sales and marketing resources.

This transaction will also expedite St. Jude Medical's entry into the high-growth intracardiac ultrasound echocardiography (ICE) market with the EP MedSystems ViewMate II intracardiac ultrasound system and the next generation ViewFlex PLUS ICE catheter scheduled for market release this quarter. This market is growing at an estimated 25 percent to 30 percent per year and includes both electrophysiology and interventional cardiology applications.

"This transaction will accelerate the growth of St. Jude Medical's program to help physicians cure atrial fibrillation," said Daniel J. Starks, chairman, president and chief executive officer of St. Jude Medical. "EP MedSystems' new ClearWave signal recording technology and its next generation ViewFlex PLUS ICE catheter will be especially important additions to our AF technology platform."

David Bruce, president and chief executive officer of EP MedSystems, said, "With growth accelerating over the past year, EP MedSystems' products and market position are stronger than they've ever been thanks to the focus and efforts of our employees. This transaction delivers significant shareholder value and enables our key product platforms to benefit from the extensive worldwide distribution, customer support and product development infrastructure of St. Jude Medical. We look forward to working with the St. Jude Medical team toward a seamless combination."

The transaction is subject to certain closing conditions and regulatory approvals, and approval by EP MedSystems shareholders. Following the close of the transaction, Bruce is expected to join St. Jude Medical, and EP MedSystems will become part of the Atrial Fibrillation division of St. Jude Medical.

In connection with the transaction, Gibson, Dunn & Crutcher, LLP is serving as legal counsel for St. Jude Medical. Piper Jaffray & Co. is acting as financial advisor to EP MedSystems, and Morgan, Lewis & Bockius LLP is serving as legal counsel for EP MedSystems.

Earnings Webcast Information:

As previously announced, St. Jude Medical will hold a webcast to discuss its first quarter 2008 financial results on Wednesday, April 16, 2008, at 8:00 a.m. CDT. St. Jude Medical will also discuss this transaction at that time. The webcast can be accessed at www.sjm.com.

ABOUT ST. JUDE MEDICAL

St. Jude Medical is dedicated to making life better for cardiac, neurological and chronic pain patients worldwide through excellence in medical device technology and services. St. Jude Medical has five major focus areas that include: cardiac rhythm management, atrial fibrillation, cardiac surgery, cardiology and neuromodulation. Headquartered in St. Paul, Minn., St. Jude Medical employs approximately 12,000 people worldwide. For more information, visit www.sjm.com.

FAVRILLE INCORPORATED (NASD: FVRL) "Up 4.44% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/FVRL.php

Favrille, Inc., a biopharmaceutical company, focuses on the development and commercialization of immunotherapies for the treatment of cancer and other diseases of the immune system in the United States. Its technology enables in manufacturing immunotherapy products that are designed to stimulate a patient's immune system to mount a specific and sustained response to diseases. The company's lead product candidate, FavId, which is in Phase III clinical trials, is used for the treatment of B-cell non-Hodgkin's lymphoma. It also develops FAV-201 for the treatment of T-cell lymphoma. In addition, Favrille has ongoing preclinical studies to assess the applicability of its technology to autoimmune diseases, with an initial focus on multiple sclerosis. It has a clinical supply and study agreement with Berlex Laboratories, Inc. The company was founded in 2000 and is headquartered in San Diego, California.

FVRL News:

April 9 - Favrille Announces Data Cutoff for Phase 3 Registration Trial of Specifid; Data Analysis and Unblinding Expected in June

Favrille, Inc. (NASD: FVRL), a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, announced today that it has reached the data cutoff date for the Company's Phase 3 registration trial of Specifid (mitumprotimut-T, formerly FavId ) following Rituxan in patients with follicular B-cell non-Hodgkin's lymphoma (NHL). As of the data cutoff date, 205 of the 349 patients randomized have experienced disease progression (relapsed) according to investigator determination. Final analysis will be based on a central radiology assessment of the patients' CT scans. Unblinding of the data is expected to occur in June 2008.

Median follow-up for ongoing patients is 31 months from randomization (range 21 to 41 months), or approximately 34 months from the initiation of Rituxan treatment (range 24 to 44 months). Based on the protocol's assumptions, this range of follow-up would provide sufficient power to detect a significant difference between the two arms for time to progression (TTP), the primary endpoint in the trial.

"We believe the design and execution of this registration trial have positioned us well for success," said John P. Longenecker, Ph.D., President and Chief Executive Officer of Favrille. "Based on the status of patients at data cutoff and our assumptions about the behavior of the control arm in this trial, we are very encouraged that the upcoming analysis will provide an outcome which is both clinically and statistically significant. Our clinical and biometrics team is working diligently to gather the required information and prepare for the analysis and unblinding of the trial in June."

Favrille initiated its Phase 3 randomized, placebo-controlled, double-blind registration trial of Specifid for follicular B-cell NHL in July 2004. The Company completed enrollment in January 2006 with 349 patients randomized into the trial in a span of 18 months. The trial was open to both treatment-naive and previously treated patients, ultimately enrolling a much larger treatment-naive population (78%). Patients were randomized at a one-to-one ratio to receive either Specifid or placebo following a standard course of Rituxan. A total of 45 patients came off study and were permanently censored for reasons other than disease progression, 28 (8%) because Specifid was not produced and 17 (5%) for a variety of other reasons. The trial was conducted at 67 centers in the U.S. under a Special Protocol Assessment granted by the U.S. Food and Drug Administration (FDA). Specifid was also granted Fast Track status by the FDA in January 2006.

In October 2007 an independent Data Monitoring Board (DMB) conducted an administrative analysis of the unblinded control arm in the Phase 3 trial. The objective of this analysis, conducted in agreement with the FDA, was to assess the behavior of disease progression in the control arm in order to help determine the duration of follow-up needed prior to unblinding the trial. The outcome of this DMB analysis supported the rationale for the timing of data cutoff.

ABOUT SPECIFID

Specifid (mitumprotimut-T, formerly FavId) is a personalized, active immunotherapy designed to stimulate a patient's immune system to mount a specific and sustained response to the patient's cancer. Specifid is based upon a recombinant protein, called idiotype (Id), which is derived from genetic material obtained from a patient's own tumor, then conjugated to keyhole limpet hemocyanin (KLH), a protein commonly used to boost immune responses. Favrille's unique and proprietary manufacturing process, which includes an insect cell (baculovirus) expression system, allows for the manufacture of Specifid for delivery to patients in as few as eight weeks. Data presented at the American Society of Hematology Annual Meeting in December 2007 showed that Id-KLH produced via insect cells results in a more immunogenic response compared to Id-KLH produced in a traditional mammalian cell manufacturing process. Also, unlike other Id-KLH active immunotherapies in development, Specifid is intended for use as a chronic therapy and is administered until the patient's disease progresses.

CARDIO INFRARED TECHNOLOGIES (OTC: CIRT) "Up 262.50% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/CIRT.php

Cardio Infrared Technologies, Inc is a technology and marketing company, which is focused on developing the revolutionary and evolutionary process of combining exercise equipment with medical benefits that go far beyond the normal benefits of standard exercise equipment. Cardio Infrared Technologies, Inc. is committed to continue to market this equipment to the exercise and medical markets and to aggressively expand the market to every country around the world. The equipment has already been featured on Good Morning America and The View. Cardio Infrared Technologies, Inc. also has an aggressive growth plan that includes acquisitions and development of innovate new equipment in the exercise and medical industries.

CIRT News:

April 8 - Cardio Infrared Technologies Ships Units Sold At Anti-Aging Show

Cardio Infrared Technologies, Inc. (OTC: CIRT), a leading Health and Wellness technology and marketing company, announced those shipments of the Cardio-Cor units that were sold during and after the Anti-Aging Show in Las Vegas, Nevada in December 2007 began shipping the week of March 3, 2008.

Wayne Bailey, President and CEO of Cardio Infrared Technologies, Inc., stated, "Sales of the Cardio-Cor are requiring an unusually long sales process; more than Cardio's normal sales within our target market. Purchasers existing facilities are already cramped for space from existing treatment and procedure equipment. If an existing facility wants to purchase a Cardio-Cor Exerbike they must often remove and relocate existing equipment or treatment areas and add to or expand their current facility. This process usually requires reallocation of resources to expand and or locate a new lease and often move to a new location. Cardio Infrared Technologies, Inc. is working with a number of clients that are in this process and will be ready for units to be delivered soon."

Cardio Infrared Technologies, Inc. has a significant back log of customers in various stages of moving, building, expanding or awaiting to complete start-up facilities so that they can complete their purchase and take delivery of the Cardio-Cor units.

COTTON & WESTERN MINING (OTC: CWRM) "Up 25.00% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/CWRM.php

Cotton & Western Mining, Inc. (the "Corporation"), a pubic corporation traded under the symbol CWRM, was founded in early 2005 as a Nevada Corporation by Robert L. Cotton, with a specific plan and goal in mind; that being, to operate a low cost and high profit junior "Iron Mineral Mining" company. Iron ore mining can be a simple low-tech process or a very expensive and sophisticated undertaking.

CWRM News:

April 9 - Cotton & Western Mining, Inc. Set to Undertake $52 Million Domestic Mill Scale Waste Project

Cotton & Western Mining, Inc. (OTC: CWRM) announced that the company is in the process of preparing to screen and magnetically scrub the 400,000 metric tons of Mill Scale that was left abandoned after the closer of a domestic steel mill.

Until recently it would not have been feasible to transport the materials from the Midwest United States to a seaport for export; however, recent surges exceeding $130.00 per dry metric ton in Spot Sales for steel making materials has awaken this project. The materials range between 67 and 72% Fe. The cargo will be transported via unit train to the Gulf of Mexico, Port of New Orleans, Louisiana and shipped via PanaMax to the People's Republic of China.

Financing for the project is being undertaken by the LC Xchange, Inc. Houston, Texas U.S.A.

The CWRM Board of directors approved this project to produce financial activity for the company during the pending permit process for the company's Baja Pacific Mining Project; which has been delayed until the third quarter of year 2008.

WHAT IS MILL SCALE?

Mill Scale consists primarily of magnetite, Fe3O4, of characteristic blue-gray "steely" color. An extremely thin outer film of hematite, Fe2O3, is invisible to the naked eye. The inner portion of the magnetite contains fine metal grains and sometimes, residual black FeO (see below), which contribute to the roughness of de-scaled metal. Mill Scale is found on all hot-rolled steel products unless processed in a protective atmosphere.

At hot-rolling temperatures, an inner layer of wustite, FeO, exists between the steel and magnetite. At elevated temperatures, FeO constitutes about 85% of the scale thickness, Fe3O4 about 10 to 15% and Fe2O3 about 0.5 to 2%. During slow cooling (below 1040 F) of hot-rolled coils of hot-rolled strip (and heavy shapes), most of the FeO is transformed to Fe and Fe3O4, and the latter oxide is predominant after cooling.

ABOUT OTCPICKS.COM

OTCPicks.com is an Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Profile Research Reports authored by our financial writers. We publish a daily Newsletter to subscribers, and we publish our Daily Market Movers Digest which is sent out on the M2 Presswire several times daily highlighting hot OTC and OTCBB stocks. To feature a company on our web site or in our daily Newsletter or Market Mover's Digest, please contact our publisher, Brian Dean at 972-546-3740, or via email at [e-mail].

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE: The OTCPicks.com employees are NOT Registered as an Investment Advisor in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold OTCPicks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. OTCPicks.com has been compensated four hundred thousand free trading shares from a non-controlling third party for MPPC advertising and promotional services. OTCPicks.com has been compensated five thousand dollars by a third party for CWRM advertising and promotional services. For a complete list of disclosures go to http://www.otcpicks.com/disclosure_details.php. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCPicks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCPicks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTCPicks.com and its affiliates are not registered investment advisors or a broker dealers. OTCPicks.com has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor's sole risk. OTCPicks.com also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTCPicks.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCPicks.com. OTCPicks.com owners may or may not hold positions in the companies that are profiled.

The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. Factors that could cause actual results to differ include the size and growth of the market for the company's products, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, pricing pressures, etc. Investing in securities is speculative and carries risk. Past performance does not guarantee future results.

Third Party Web Sites and Information:

OTCPicks.com and newsletter may provide hyperlinks to third party websites or access to third party content. OTCPicks.com does not control, endorse, or guarantee content found in such sites. You agree that OTCPicks.com is not responsible for any content, associated links, resources, or services associated with a third party site. You further agree that OTCPicks.com shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only.

CONTACT: Brian Dean, Publisher, OTCPicks.com Tel: [phone] e-mail: [e-mail]

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [e-mail].




(C)1994-2008 M2 COMMUNICATIONS LTD
**********************************************************************
As of Saturday, 04-05-2008 23:59, the latest Comtex SmarTrend? Alert, an automated pattern recognition system, indicated a DOWNTREND on 03-18-2008 for FVRL @ $1.35.

For more information on SmarTrend, contact your market data provider or go to www.mysmartrend.com

SmarTrend is a registered trademark of Comtex News Network, Inc. Copyright ? 2004-2008 Comtex News Network, Inc. All rights reserved.

-0-